Vaxxinity, Inc. Class A Common Stock/VAXX

$0.74

3.37%
-
1D1W1MYTD1YMAX

About Vaxxinity, Inc. Class A Common Stock

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.

Ticker

VAXX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mei Mei Hu

Employees

87

Headquarters

Dallas, United States

VAXX Metrics

BasicAdvanced
$87.45M
Market cap
-
P/E ratio
-$0.52
EPS
-
Beta
-
Dividend rate

What the Analysts think about VAXX

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
1,386.49% upside
High $15.00
Low $7.00
$0.74
Current price
$11.00
Average price target

VAXX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-13.1M
-5.76%
Profit margin
0%
-

VAXX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.67%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.16
-$0.15
-$0.11
-$0.10
-
Expected
-$0.16
-$0.16
-$0.16
-$0.12
-$0.10
Surprise
0%
-6.25%
-29.03%
-16.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Vaxxinity, Inc. Class A Common Stock stock

Buy or sell Vaxxinity, Inc. Class A Common Stock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing